secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2022-09-12T23:59:59+00:00
Accession:  0001564590-22-031438
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyra presents additional Phase 2 LANTERN data for LYR-210 at ARS meeting
------------------------------------------------------------------------

- Posted slide presentation with additional Phase 2 results from LANTERN trial of LYR-210 for chronic rhinosinusitis.
- Data presented at 68th Annual Meeting of the American Rhinologic Society on September 10, 2022.
- Top-line results from LANTERN previously reported on April 11, 2021; this update includes further analysis.
- Slide deck available on Lyra's investor website and attached as exhibit to the 8-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000156459022031438/0001564590-22-031438-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000156459022031438/lyra-8k_20220910.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-031438

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer